Table 1.

Patient demographics, treatment received, and clinical outcome. M, male; F, female; PR, partial response; SD, stable disease; PD, progressive disease.

Patient	Age (years)/ sex	Tumor site*	Tumor mesothelin expression†	No. of previous therapies	No. of SS1P cycles received	Overall tumor response‡	Delayed tumor response§	Post-study chemotherapy	Response to post-study chemotherapy	Overall survival (months)
2	50/M	Peritoneum	100%, 3+	2	2	PR (−44%)	Yes (7 months)	—	—	18.2+
3	56/F	Pleura	100%, 3+	2	6	PR (−74%)	—	—	—	17.1+
4	67/F	Pleura	100%, 3+	3	2	SD	—	Yes	PR (−55%)	14
5	51/M	Peritoneum	100%, 3+	4	4	PR (−70%)	—	—	—	14.5+
6	43/M	Pleura	100%, 3+	4	2	SD	—	—	—	8.8
7	48/F	Pleura	90%, 3+	2	2	PD	—	—	—	6.2
8	60/M	Pleura	100%, 2+	6	2	PD¶	—	—	—	5.7
9	52/F	Pleura	70%, 2+	5	2	PD	Yes (4 months)∥	Yes	85% decrease in tumor FDG uptake**	10.6+
10	62/M	Pleura	30%, 2+	2	2	PD	—	—	—	4.2
11	65/M	Pleura	50%, 3+	1	2	SD	—	Yes	No	7.3

^*All patients had epithelial-type mesothelioma.

^†Mesothelin expression was determined by immunohistochemistry and presented as percentage of positive cells, and the degree of staining intensity (absent; 1+, mild; 2+, moderate; or 3+, strong) is shown.

^‡For patients with tumor response, the percent decrease in the sum of target lesions is shown.

^§Months from study initiation to the time when response was first observed.

^¶Patient 8 had progressive disease due to new brain metastasis but had a 10% reduction in target lesions.

^∥Patient 9 had initial progressive disease but, at 4 months, had a 25% reduction in size of one of the target lesions and a marked decrease in metabolic activity by PET.

^**Patient 9 had an 85% reduction in tumor SULpeak/cm³ compared to baseline PET scan and stable disease by CT scan on post-study chemotherapy.